Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | January 6, 2021 | News story | Research and Development | COVID-19, Vaccine
In the first week of 2021, the global COVID-19 vaccination race continues to dominate the news. The EU states have secured an additional 100 million doses of the Pfizer-BioNTech vaccine, while both Israel and India approve coronavirus jabs for use.
The Phase III trial of Moderna’s vaccine offering provides promising results, while a collaboration between Emergex and Brazil’s Bio-Manguinhos to develop a COVID-19 jab is underway.
1. Moderna’s COVID-19 vaccine achieves over 90% efficacy in Phase III trial – Published 04/01/2021
According to the results published in the New England Journal of Medicine, the two-dose regime of the biotechnology company’s vaccine was given 28 days apart, was well-tolerated, and demonstrated vaccine efficacy of 94.1% against COVID-19.
2. Concern as India approves COVID-19 vaccine before trial completion – Published – 04/01/21
Experts have expressed concern over India’s emergency approval of its homegrown COVID-19 vaccine, Covaxin, before studies have been completed.
3. EU states to receive 100m extra doses of Pfizer-BioNTech vaccine – Published 04/01/21
Pfizer and BioNTech have announced they will supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY, to the EU’s 27 member states in 2021.
4. Emergex to collaborate with Bio-Manguinhos on new COVID-19 vaccine – Published on 05/01/21
Emergex, a company focusing on the development of medicines against viral and bacterial infectious diseases, has announced a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos), part of the Oswaldo Cruz Foundation (Fiocruz) in Brazil, to develop a COVID-19 vaccine.
5. Israel authorises Moderna’s COVID-19 vaccine for use – Published 05/01/21
Israel has secured six million doses of the company’s vaccine, and the first deliveries are expected to begin soon. It is the third country to authorise the Moderna jab, following the US and Canada in December.
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
